[Neogenomics Logo]

                                NEOGENOMICS, INC
                                  PRESS RELEASE

Investor Relations Contact:
NeoGenomics, Inc.
Mr. Steven Jones
(239) 598-0964
sjones@neogenomics.org

12701 Commonwealth Drive, Suite 9
Ft. Myers, FL  33913

FOR IMMEDIATE RELEASE

              NeoGenomics, Inc. Announces New Equity Financing and
                    Planned Amendments to its Credit Facility

        Ft. Myers, Florida - January 26, 2006 - NeoGenomics, Inc. (NASD OTC BB:
NGNM) today announced that it had reached agreements for up to $600,000 of new
equity financing for the Company as well as planned amendments to its credit
facility. As part of these agreements, a new investor to the Company has
purchased 2.0 million restricted shares of the Company's common stock at a
purchase price $0.20/share, which has resulted in $400,000 of new equity capital
coming into the Company. This investor was also granted a warrant to purchase
900,000 shares of common stock at an exercise price of $0.26/share. As part of
the equity agreements and planned credit facility amendment, the Company also
granted the right to purchase an additional $200,000 of equity under the same
terms by April 30, 2006 to Aspen Select Healthcare, LP ("Aspen") the Company's
largest shareholder and creditor, provided that if Aspen elects not to exercise
such rights, then the Company may make such shares available for purchase to the
new investor.

        Under the terms of the planned credit facility amendment, the Company and
Aspen have agreed to extend the maturity date until September 30, 2007 and
increase the availability of such credit facility by up to $200,000 in certain
circumstances. In addition to other items, the planned amendment will provide
the company with the ability to access up to $500,000 in secured vendor
financing and/or lease arrangements.

        Robert Gasparini, the Company's President, stated, "I am very pleased with
this financing package. The equity components are at terms more favorable than
the current market price of our stock and are with investors who have a
long-term commitment to the Company. In addition, we believe the credit facility
amendments will provide the flexibility to fuel further growth and expansion
where it makes financial sense in lieu of issuing additional equity."




                                       1




        Mr. Gasparini added, "Operationally, the Company is doing great. We are
experiencing very strong growth across the board in all our core testing
services. While we are still completing our year-end audit and won't be
releasing our 2005 fourth quarter and fiscal year financial results until late
February or early March, I can report that after a record Q2 and Q3, our testing
volumes increased another 23% in the fourth quarter of 2005 from the third
quarter. In addition, we are experiencing very strong growth this month and
expect that our testing volumes will increase another 15-20% sequentially from
December. Given our current momentum, we anticipate that we will be profitable
on a monthly basis by the end of the first quarter, and we believe this will be
the final financing package for our current business plan."

        A more complete description of the terms of these financings is included
with the Company's report on Form 8-K, which was filed with the SEC yesterday.

About NeoGenomics, Inc.

        NeoGenomics, Inc. is a clinical laboratory that offers genetic and
molecular cancer diagnostic testing services. NeoGenomics is headquartered in
Fort Myers, FL and services the needs of the oncologists, pathologists and
hospitals throughout the United States. For additional information about
NeoGenomics, please visit our website at www.neogenomics.org.

Forward Looking Statements

        Except for historical information, all of the statements, expectations and
assumptions contained in the foregoing are forward-looking statements. These
forward looking statements involve a number of risks and uncertainties that
could cause actual future results to differ materially from those anticipated in
the forward looking statements, including, but not limited to, the Company has
incurred significant losses since its inception and has experienced negative
operating margins and negative cash flows from operations, any adverse effect or
limitations caused by governmental regulations, the company's ability to attract
and retain qualified personnel, to initiate and develop client relationships, to
gain market acceptance of service offerings, as well as other risks described
from time to time in the company's filings with the Securities and Exchange
Commission. Although the Company has used its best efforts to be accurate in
making those forward-looking statements, there can be no assurance that the
assumptions made by management will materialize. In addition, the information
set forth in the Company's Form 10-KSB for the fiscal year ended December 31,
2004, describes certain additional risks and uncertainties that could cause
actual results to vary materially from the future results covered in such
forward-looking statements. The Company undertakes no obligation to publicly
revise or update the forward looking statements to reflect new information,
subsequent events or otherwise.



                                       2